Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sangamo Therapeutics Inc

0.5250
-0.0222-4.06%
Post-market: 0.53780.0128+2.44%19:59 EDT
Volume:2.59M
Turnover:1.39M
Market Cap:158.40M
PE:-1.86
High:0.5600
Open:0.5600
Low:0.5250
Close:0.5472
52wk High:3.18
52wk Low:0.4111
Shares:301.71M
Float Shares:239.00M
Volume Ratio:0.56
T/O Rate:1.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2826
EPS(LYR):-0.4856
ROE:-292.47%
ROA:-41.15%
PB:8.08
PE(LYR):-1.08

Loading ...

Sangamo Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 05

Sangamo Therapeutics Announces Promising Phase 1/2 Clinical Data for Gene Therapy in Fabry Disease at ICIEM2025

Reuters
·
Sep 04

Sangamo Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 08

BRIEF-Sangamo Therapeutics Q2 EPS USD -0.08 Vs. IBES Estimate USD -0.13

Reuters
·
Aug 08

Sangamo Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview

Reuters
·
Aug 06

Sangamo Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview

Reuters
·
Aug 01

Sangamo Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 25

Sangamo Therapeutics Says Phase 1/2 Fabry Disease Study Showed Favorable Safety Profile; Shares Up Pre-Bell

MT Newswires Live
·
Jun 24

BRIEF-Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

Reuters
·
Jun 24

Sangamo Therapeutics Receives Key FDA Designations and Advances Towards 2026 BLA Submission for Fabry Disease Gene Therapy

Reuters
·
Jun 24

Sangamo Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
Jun 17

Sangamo Therapeutics Is Maintained at Overweight by Barclays

Dow Jones
·
May 14

Top Premarket Decliners

MT Newswires Live
·
May 13

Sangamo Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

BRIEF-Sangamo Therapeutics Q1 EPS USD -0.14 Vs. IBES Estimate USD -0.13

Reuters
·
May 13

Sangamo Therapeutics Reports Q1 2025 Net Loss of $30.6 Million, Down from $49.1 Million in 2024; EPS Improves to $0.14 Loss from $0.27

Reuters
·
May 13

Sangamo Therapeutics Launches $23 Million Share Offering with Warrants Priced at $0.50 Each

Reuters
·
May 13